Modulators of toll-like receptors

A compound of Formula II:

• or a pharmaceutically acceptable salt or tautomeric enol thereof, wherein:
• Y—Z is —CR4R5—;
• L1 is —NR8—, —O—, —N(R8)C(O)—, or a covalent bond;
• R1 is alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, C1-C6 substituted or unsubstituted heteroalkyl containing one or more heteroatoms (selected from N, O, or S), -cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, bicyclo[3.1.0]cyclohexyl, tetrahydropyranyl, substituted tetrahydropyranyl, furanyl, substituted furanyl, pyrrolidinyl, or substituted pyrrolidinyl;
• X1 is alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, or a bond;
• D is phenylene, biphenylene, or pyridinyl, wherein said phenylene, biphenylene, or pyridinyl is substituted with one or two -L2-NR6R7;
• each L2 is independently alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, or a covalent bond;
• each R3 is independently halogen, cyano, azido, nitro, alkyl, substituted alkyl, hydroxyl, amino, alkoxy, haloalkyl, haloalkoxy, —CHO, —C(O)OR8, —S(O)R8, —S(O)2R8;
• —C(O)NR9R10, —N(R9)C(O)R8, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, —S(O)2NR9R10, —N(R9)S(O)2R8, —N(R9)S(O)2OR10, or —OS(O)2NR9R10;
• n is 0, 1, 2, 3, 4 or 5;
• R4 and R5 taken together with the carbon to which they are attached is —C(O)—;
• R6 and R7 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, haloalkyl, C1-C6 substituted or unsubstituted heteroalkyl containing one or more heteroatoms (selected from N, O, or S), C(O)H, —C(O)R8, —S(O)R8, —S(O)2R8, —C(O)OR8, or —C(O)NR9R10, S(O)2NR9R10;
• or
• R6 and R7, taken together with the nitrogen to which they are both attached, form a substituted or unsubstituted heterocycle, which may contain one or more additional heteroatoms selected from N, O, P, or S;
• or
• R7 taken together with L2, and the N to which they are both attached, forms a substituted or unsubstituted 3 to 8 membered heterocycle which may contain one or more additional heteroatoms selected from N, O, S, or P;
• R8 is H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or C1-C6 substituted or unsubstituted heteroalkyl containing one or more heteroatoms (selected from N, O, or S);
• and
• R9 and R10 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, haloalkyl, C1-C6 substituted or unsubstituted heteroalkyl containing one or more heteroatoms (selected from N, O, or S);
• wherein each substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cyclopropyl, substituted cyclobutyl, substituted cyclopentyl, substituted cyclohexyl, substituted tetrahydropyranyl, substituted furanyl, or substituted pyrrolidinyl, substituted alkylene, substituted heteroalkylene, substituted alkenylene, substituted alkynylene is independently substituted with one to four substituents selected from the group consisting of -halogen, —R, —O−, ═OR, —SR, —S−, —NR2, —N(+)R3, ═NR, —C(halogen)3, —CR(halogen)2, —CR2(halogen), —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NRC(═O)R, —NRC(═O)OR, —NRC(═O)NRR, —C(═O)NRR, —C(═O)OR, —OC(═O)NRR, —OC(═O)OR, —C(═O)R, —S(═O)2OR, —S(═O)2R, —OS(═O)2OR, —S(═O)2NR, —S(═O)R, —NRS(═O)2R, —NRS(═O)2NRR, —NRS(═O)2OR, —OP(═O)(OR)2, —P(═O)(OR)2, —P(O)(OR)(O)R, —C(═O)R, —C(═S)R, —C(═O)OR, —C(═S)OR, —C(═O)SR, —C(═S)SR, —C(═O)NRR, —C(═S)NRR, —C(═NR)NRR, and —NRC(═NR)NRR;
• wherein each R is independently H or alkyl.